Shares of Viking Therapeutics, Inc. (NASDAQ: VKTX) traded at a new 52-week high today and are currently trading at $14.99. So far today, approximately 48.12M shares have been exchanged, as compared to an average 30-day volume of 2.64M shares.
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company’s lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211.
Mentions of Viking Therapeutics, Inc. on Twitter in the past 24 hours have totaled 1,123, as compared to 45 in the prior 24 hours (a change of 2,396%). On Stocktwits, posts totaled 716 for the same period, as compared to 25 in the prior 24 hours (a change of 2,764%).
Viking Therapeutics, Inc. share prices have moved between a 52-week high of $11.99 and a 52-week low of $2.02. The stock has moved -4.8% over the past week.
To learn more about Viking Therapeutics, Inc., visit the company’s website at https://www.vikingtherapeutics.com.
Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected
About IBN
IBN consists of financial brands introduced to the investment public over the course of 17+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.
Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
